Ranked #1
The Metastatic Breast Cancer project: a novel patient-partnered initiative
The Metastatic Breast Cancer project: a novel patient-partnered initiative
In this podcast, Marina Parry, ESMO Open Digital Editor, speaks to Elana Anastasio, Partnership Outreach Manager, and Br... Read more
5 Sep 2018
•
26mins
Ranked #2
Highlights in Lung Cancer 2019
Highlights in Lung Cancer 2019
There has been a lot of exciting trials in lung cancer reported in 2019. In this podcast, Jonathan Lim (YOC member) spea... Read more
20 Dec 2019
•
26mins
Similar Podcasts
Ranked #3
ESMO Presidential Symposium: Phase III PAOLA-1: Olaparib in newly diagnosed, advanced ovarian cancer
ESMO Presidential Symposium: Phase III PAOLA-1: Olaparib in newly diagnosed, advanced ovarian cancer
The present podcast gives a short summary of the PAOLA-1 trial investigating the addition of Olaparib to bevacizumab as ... Read more
24 Sep 2019
•
5mins
Ranked #4
The ESMO-Magnitude of Clinical Benefit Scale Group
The ESMO-Magnitude of Clinical Benefit Scale Group
Despite all the efforts done so far, access to essential drugs in Oncology is still asymmetric. In this podcast, Teresa ... Read more
9 Sep 2019
•
16mins
Ranked #5
ESMO 2018 Presidential Symposium – IMpassion130: Atezolizumab in triple negative breast cancer
ESMO 2018 Presidential Symposium – IMpassion130: Atezolizumab in triple negative breast cancer
The IMpassion130 trial was a global, randomized, double-blind, Phase III study of Atezolizumab + nab-paclitaxel vs. plac... Read more
4 Oct 2018
•
9mins
Ranked #6
ESMO Presidential Symposium: Final overall survival analysis from the FLAURA trial
ESMO Presidential Symposium: Final overall survival analysis from the FLAURA trial
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival ana... Read more
26 Sep 2019
•
6mins
Ranked #7
Immune checkpoint inhibitors for every non-small cell lung cancer patient
Immune checkpoint inhibitors for every non-small cell lung cancer patient
Several phase III trials on immune checkpoint inhibitor therapy in non-small cell lung cancer were recently published an... Read more
17 Jul 2018
•
16mins
Ranked #8
Current biomarkers in immunotherapy
Current biomarkers in immunotherapy
Immunotherapy approaches have revolutionized medical oncology in the last years. However, still only a fraction of patie... Read more
3 Oct 2019
•
4mins
Ranked #9
Highlights from the ESMO Symposium on Signalling Pathways in Cancer 2016
Highlights from the ESMO Symposium on Signalling Pathways in Cancer 2016
A critical review of the highlights of the ESMO Symposium on Signalling Pathways in Cancer 2016, held March 2016 in part... Read more
4 Apr 2016
•
11mins
Ranked #10
Reimbursement Reality for Off-label use (OLU) of Drug Treatments in Cancer Care
Reimbursement Reality for Off-label use (OLU) of Drug Treatments in Cancer Care
In this podcast, Marina Parry, ESMO Open Digital Editor, speaks to Amanda Herbrand, Medical Oncologist Trainee working a... Read more
22 Sep 2019
•
18mins
Ranked #11
Biosimilars in oncology
Biosimilars in oncology
Biosimilars will soon become broadly available in the oncology field, raising important questions from both patients and... Read more
24 Jul 2018
•
9mins
Ranked #12
Questions asked in everyday practice: Immune Checkpoint Inhibitors
Questions asked in everyday practice: Immune Checkpoint Inhibitors
Immunotherapy has been approved for several indications in Oncology, resulting in an increasing number of physicians tha... Read more
4 Jun 2018
•
14mins
Ranked #13
Epigenetic Biomarkers in Cancer
Epigenetic Biomarkers in Cancer
Epigenetic biomarkers are emerging across tumor types in cancer research. Aberrant DNA methylation in tumors results in ... Read more
26 Jun 2018
•
9mins
Ranked #14
ESMO Presidential Symposium: ClarIDHy - ivosidenib in patients with advanced cholangiocarcinoma
ESMO Presidential Symposium: ClarIDHy - ivosidenib in patients with advanced cholangiocarcinoma
Advanced cholangiocarcinoma is associated with a particular impaired survival prognosis. So far targeted therapies with ... Read more
12 Feb 2020
•
7mins
Ranked #15
News on the horizon in glioblastoma therapy
News on the horizon in glioblastoma therapy
Glioblastoma is the most frequent primary malignant brain tumor in adults. Methylation of the O-6-methylguanine-DNA meth... Read more
29 Jan 2020
•
12mins